Why Colombia is moving flower into pharmacies in 2025
Colombia’s medical cannabis framework has existed for years, but patient access has largely centered on oils, extracts, and a limited set of finished products—often through specialized channels rather than everyday retail pharmacy workflows. In late July 2025, the national government published a draft decree that would explicitly authorize pharmacies (droguerías) to dispense medical cannabis flower when supported by a physician prescription, tightening rules for dispensing, patient verification, and marketing.
This proposal builds on Decree 811 of 2021, which already modernized several aspects of Colombia’s medicinal-use rules, including pathways that supported broader product forms and domestic distribution. The 2025 draft decree is best understood as an operational “last-mile” measure: it is aimed at normalizing access inside Colombia by using the existing pharmacy network, while still treating flower as a controlled, prescription-only item.
This article summarizes what the draft decree signals for Colombia medical cannabis pharmacies 2025: expected dispensing rules, likely prescription and patient-record requirements, INVIMA’s role, advertising/display restrictions, and how producers—especially those built around export-only models—should prepare for a domestic pharmacy rollout.
Important: This is informational only and not legal advice. Draft regulations can change before final publication.
Regulatory baseline: how the 2025 draft relates to Decree 811/2021
Decree 811/2021 is widely referenced as the foundation for Colombia’s modern medical cannabis regulations, including recognition of additional product formats and the alignment of different authorities’ roles (licensing, health oversight, and controlled-substance handling). The July 2025 draft decree does not replace that system; it appears designed to clarify pharmacy dispensing as a standard channel for flower, and to define guardrails so that dispensing looks and behaves like other controlled prescription medicines.
For businesses, the practical takeaway is that the draft decree is likely to:
- Reaffirm that flower is medical-only, prescription-based, and tied to controlled-substance handling.
- Place droguerías and pharmacists at the center of compliance—records, identity checks, secure storage, and counseling.
- Add or formalize patient-level traceability and stronger anti-diversion measures.
If you need the current baseline text for Colombia’s medical framework, start with official sources and consolidated references:
What the draft decree is trying to solve
From a policy perspective, the July 2025 proposal targets several persistent issues:
Expanding “in-country” access beyond extracts
Even when cultivation and manufacturing capacity exists, domestic access can lag if products are concentrated in non-pharmacy channels or in forms that patients do not prefer. The draft proposes a clear route for prescription flower to be dispensed through pharmacies, which could reduce friction for patients and prescribers.
Regulators typically view flower as a higher diversion risk and a higher “misuse optics” risk than oils/capsules, even when medically prescribed. The draft’s emphasis on pharmacist controls and identity checks aligns with that risk profile.
A major commercial implication is that a pharmacy channel would require:
- SKU standardization (consistent THC/CBD ranges, packaging formats, stability data)
- pharmacy-friendly labeling and warnings
- repeatable distribution logistics and stock management
Licensing and who can participate (what changes, what doesn’t)
The draft decree is focused on dispensing, not rewriting upstream licensing. That means core licensing still stems from Colombia’s existing medical regime (cultivation, manufacturing, and related authorizations).
What may change in practice is who becomes commercially relevant:
- Pharmacies (droguerías) and pharmacy chains become primary retail endpoints.
- Wholesale/distribution functions become more important—especially for GMP-aligned, batch-traceable supply.
- Manufacturers will need to align product presentation and documentation to pharmacy and INVIMA expectations.
Business takeaway: Even if your licensing is already in place, pharmacy rollout can create “secondary compliance”—contracts, SOPs, training, returns/destruction procedures, and audit readiness.
Prescription requirements: what to expect for “flower by prescription”
A central question for Colombia medical cannabis pharmacies 2025 is how strict prescribing will be and what must appear on the prescription. While the final decree will control, the draft’s direction suggests a model similar to other controlled prescription products:
Likely prescription content elements
Expect requirements such as:
- Patient identification (full name and national ID)
- Prescriber identification (professional registration, contact information)
- Clinical indication (diagnosis or treatment justification, depending on format)
- Product specification (flower form, cannabinoid content or range, presentation, quantity)
- Directions for use (route of administration guidance, frequency, maximum daily amount)
- Refill/renewal rules (limits on repeats, validity period)
Repeat dispensing and renewals
Many jurisdictions restrict refills for controlled substances. Colombia may similarly require either:
- a new prescription for each dispensation, or
- time-limited repeat authorization with strict quantity caps.
Compliance note: If repeats are permitted, pharmacies should expect tighter recordkeeping and more frequent reconciliation against inventory.
Patient registry and recordkeeping: traceability, privacy, and audits
Your research note highlighted patient-registry requirements. Even if Colombia does not implement a single “national registry card,” the draft decree’s logic points to patient-level traceability similar to controlled-medicine norms.
What pharmacies will likely need to record
Expect pharmacies to maintain, for each dispense event:
- Patient identity verification (ID type and number)
- Prescription details (prescriber info, date, quantity)
- Batch/lot information (for recalls and diversion investigations)
- Dispensing pharmacist and the dispensing location
- Counseling notes or required warnings delivered
Data retention and privacy
Because this involves medical treatment data, pharmacies and operators should plan for:
- documented retention periods
- controlled access to patient data
- secure storage for any paper records
- audit-ready logs
Business takeaway: If you are supplying pharmacies, expect them to request batch documentation, certificates of analysis, and standardized product identifiers to support reconciliation and inspections.
Pharmacist controls: counseling, storage, and controlled-substance procedures
Dispensing flower in a pharmacy setting typically introduces requirements beyond “ordinary” OTC-style retail.
Secure storage and access limitations
Pharmacies should anticipate:
- restricted access storage (locked cabinets/secure rooms)
- inventory reconciliation and discrepancy reporting
- loss/theft procedures
Pharmacist gatekeeping and patient counseling
Pharmacist obligations frequently include:
- verifying prescription completeness
- reviewing patient factors (drug interactions, contraindications)
- counseling on dosing and safe use
- reinforcing warnings (impairment, driving, youth exposure)
In practice, operators should plan training modules and scripts to ensure consistent counseling and to reduce regulatory risk.
Point-of-sale identity checks and anti-diversion controls
The draft decree’s focus on point-of-sale identity checks is consistent with a controlled medicine distribution model.
What identity checks may look like
At minimum, pharmacies should expect to:
- require a valid government-issued ID matching the prescription
- document the identity check in the dispensing record
- restrict pickup to the patient (or clearly defined caregiver/representative rules, if permitted)
Red flags and refusal protocols
Pharmacies should plan written procedures for:
- suspected forged prescriptions
- repeated early refill attempts
- requests inconsistent with dosing directions
- intoxication or disruptive behavior at pickup
Compliance takeaway: These refusal protocols are not only a safety measure; they are also a defensible audit artifact during inspections.
INVIMA’s role: finished products vs. magistral preparations
A recurring source of confusion in Colombia is the boundary between:
- INVIMA-approved finished products (with formal product authorization/registration), and
- magistral preparations (compounded preparations prepared for an individual patient based on a prescription), which follow a different compliance logic.
How this likely applies to flower
If the decree authorizes flower dispensation broadly, the market could evolve along two parallel routes:
- Standardized packaged flower distributed to pharmacies with defined labeling, batch testing, and stability controls.
- Magistral preparation workflows where pharmacies or authorized compounding entities prepare patient-specific formulations (more common for oils, but the decree may clarify if and how flower can be handled within magistral rules).
What businesses should watch in the final text
Monitor whether the final decree:
- requires INVIMA authorization for packaged flower sold through pharmacies
- imposes product-category labeling rules (medicine vs. another regulated category)
- clarifies whether pharmacies can repackage or must dispense only in original manufacturer packaging
Start with INVIMA’s official guidance and publications: https://www.invima.gov.co/
Advertising, display, and marketing limits (what “pharmacy channel” usually implies)
Your brief asks specifically about advertising or display restrictions. Even without flower-specific language, Colombia’s general approach to prescription medicine advertising typically implies stronger limits than consumer goods.
Likely restrictions in a pharmacy-dispensed model
Expect rules such as:
- no direct-to-consumer advertising for prescription-only products
- no open product display or self-service access (behind-the-counter handling)
- limits on price promotions, giveaways, or loyalty-program incentives
- restrictions on medical claims beyond approved labeling
Digital marketing and informational content
Companies should assume that regulators will scrutinize:
- websites, social media posts, and influencer content
- disease claims or “guaranteed results” statements
- imagery or messaging that normalizes non-medical use
Compliance takeaway: Build a conservative marketing review process now. Align content to “informational, professional, and prescription-based” messaging with internal approvals.
Smoking/vaping guidance: likely warnings and route-of-administration sensitivity
A key operational issue is how the decree will treat smoking and vaping.
Even where flower is legal for medical use, regulators often:
- discourage smoking as a route of administration
- require respiratory risk warnings
- require counseling and labeling emphasizing medically appropriate use
What to expect in practice
Pharmacies and manufacturers should plan for:
- explicit warnings on impairment and avoiding driving
- youth exposure warnings and safe storage statements
- guidance to follow physician instructions and avoid non-prescribed routes
If the final decree contains route-of-administration constraints, it may also impact product presentation (for example, limits on accessories or any implication of recreational use).
Expected rollout timeline: Q4 2025 to Q1 2026 (and what could delay it)
Your notes anticipate an implementation window of Q4 2025/Q1 2026. That is plausible for a draft decree released in late July 2025, but the final timing depends on:
- public comment and revision
- interagency alignment (health regulator, controlled-substances oversight, enforcement)
- operational readiness for pharmacies (training, record systems)
Practical milestones to track
Businesses should watch for:
- final decree publication date and effective date
- any implementation grace period for pharmacies
- issuance of technical guidance (labeling, recordkeeping templates)
- pilot programs or phased rollout (e.g., major cities first)
Action item: Set up regulatory monitoring for Ministry of Health publications and INVIMA communications so you don’t miss the final text or implementation guidance.
Pricing and coverage: what could shape patient access
Pharmacy availability does not automatically equal affordability. Colombia’s pricing and coverage dynamics may be shaped by:
- whether products are treated like prescription medicines for reimbursement purposes
- whether EPS/insurers recognize coverage for specific indications
- whether magistral preparations remain the dominant model for individualized dosing
What to expect near launch
In an early rollout period, anticipate:
- limited product selection (few standardized SKUs)
- regional price variability based on distribution and pharmacy participation
- patient out-of-pocket payment as the default unless coverage pathways become clearer
Business implication: Producers should model demand with conservative coverage assumptions at launch, while building evidence and documentation to support broader reimbursement discussions.
Colombia has been known for export ambition—GMP-aligned facilities and international supply strategies. A pharmacy-dispensed flower channel could materially change what “success” looks like domestically.
To sell into pharmacies, producers may need:
- pharmacy-ready packaging (tamper-evident, batch/lot prominent, patient warnings)
- consistent cannabinoid specs and lot-to-lot controls
- COA packages aligned with Colombian requirements and pharmacy expectations
- recall readiness and complaint handling
- distribution agreements with clear responsibilities for returns, destructions, and discrepancies
Commercial strategy shifts
Export markets can tolerate longer lead times; pharmacies require:
- predictable replenishment
- stable pricing
- clear product education for pharmacists and prescribers
Investor takeaway: Domestic pharmacy rollout favors operators with mature quality systems, strong documentation, and the ability to support pharmacovigilance-like workflows.
Enforcement and penalties: where risk will concentrate
When a product moves into pharmacies, enforcement typically concentrates on:
- diversion (sales without valid prescription, quantity irregularities)
- recordkeeping failures (missing ID checks, incomplete logs)
- unauthorized marketing (improper claims, consumer-targeted promotions)
- quality and labeling (mismatched potency, missing warnings)
Businesses should expect inspections to focus on whether the pharmacy can prove:
- the prescription was valid
- the patient identity was verified
- the dispensed quantity matched the authorized amount
- the product lot was traceable
Compliance checklist for 2025–2026 readiness
For pharmacies (droguerías)
- Implement identity verification at point of sale and document it
- Create SOPs for prescription validation, refusals, and escalation
- Train staff on counseling, impairment warnings, and safe storage messaging
- Prepare secure storage, inventory reconciliation, and discrepancy reporting
- Establish document retention and privacy controls
For producers and manufacturers
- Align specs and labeling to pharmacy workflows and likely INVIMA expectations
- Build a standardized documentation package (batch records, COAs, stability where applicable)
- Negotiate distribution terms covering returns, destructions, and recall communications
- Prepare conservative, compliant marketing (no consumer-directed promotion)
For prescribers and clinics
- Monitor final prescribing requirements and any platform/reporting expectations
- Prepare patient education materials consistent with pharmacy counseling and warning language
Key takeaways
- The July 2025 draft decree signals Colombia’s intent to make medical cannabis flower available through pharmacies with a physician prescription, expanding in-country access beyond extracts.
- Expect a compliance-heavy model: patient identity checks, pharmacist gatekeeping, secure storage, and detailed records.
- Watch the boundary between INVIMA-authorized finished products and magistral preparations; the final text will determine which product pathways scale fastest.
- Marketing is likely to be tightly constrained, with limited display and restrictions consistent with prescription medicine rules.
- A plausible rollout window is Q4 2025 to Q1 2026, but final timing depends on decree publication and implementation guidance.
- Producers oriented to export will need to upgrade “retail readiness”: packaging, consistency, and pharmacy-facing documentation.
Stay current with Colombia’s fast-moving compliance landscape
Draft decrees can evolve quickly, and operational details—prescription format, recordkeeping fields, warning language, and enforcement priorities—often arrive through follow-on guidance.
For ongoing monitoring and practical compliance support, use https://www.cannabisregulations.ai/ to track licensing and policy updates, map requirements into SOPs, and keep your team aligned as Colombia’s pharmacy-dispensing rollout develops.
